Harbour BioMed raises undisclosed series A+

Harbour BioMed (Shanghai, China) raised an undisclosed series A+ round on Jan. 22 led by new investor CDH Investments. Existing investor Advantech Capital participated.

This month, Harbour granted BeiGene Ltd. (NASDAQ:BGNE) and ImmunoChina Pharmaceuticals Co. Ltd. rights to its H2L2 transgenic mouse platform in a pair of antibody-related deals (see BioCentury, Jan. 12 & Jan. 12). Harbour's H2L2 mice generate human mAbs with both heavy and light chains...